Burzynski Page #13

detected in the blood of the nine patients during treatment.

We compared this to the data which we have in our studies.

We found that they were severely diluting the medicine,

and this is why the patients had fluid overload.

Antineoplaston AS2-1 consists of two ingredients:

called Phenylacetate, and Phenylacehlglutamine.

And about 2.7 times lower level of Phenylacetate was

found in the patient's blood compared to

what we see in our patients' who receive successful treatment.

Phenylacehlglutamine,

there was about a 36 times lower level in patient's blood

compared to what we see in our patients who

receive the right dosage of Antineoplastons.

And the concentrations of Phenylacehlisoglutamine,

one of the main ingredients of Antineoplaston A10,

were close to one hundred and seventy times lower

than what we see in the treatment of patients with Antineoplastons.

And that's what we found out from the patients'

husbands or the patients themselves.

That's what they were doing.

So this was horrible. This was a criminal act.

They should be prosecuted for that.

Because obviously, they knew what they were doing,

and they knew that these patients had really no

chance to respond to any treatment, they were going to die.

And that's what happened. After we realized what they

were doing, we decided to force them to stop the clinical trials.

And since then obviously,

The National Cancer Institute hates us

they do whatever they can but they do not cooperate

with us anymore.

In the past,

when the NCI (National Cancer Institute) or

its assigned entity is conducting an alternative cancer therapy

[clinical trial],

they always alter the protocols and let it fail-

to discredit the therapy.

But this time the pharmacokinetic data shows that they didn't do it right.

And most scientists will not look at it carefully.

Because "papa is telling you something, and you don't question him."

Most of us would assume,

that with any story such as this, surely there's another side to it.

Our story is no exception.

After the National Cancer Institute intentionally violated all protocols

of their own Antineoplaston trials,

and after all state and federal agencies had failed

in their 14-year campaign to remove Burzynski

from society, after all of the dust settled,

a profound truth began to emerge.

It was October 4th, 1991, that America's National Cancer Institute

hosted their site visit to Burzynski's clinic,

and verified for themselves that "anti-tumor activity was

documented by the use of Antineoplastons."

Seventeen days later, on October 21st, 1991,

The United States of America as represented by the

Department of Health and Human Services,

and Dr. Dvorit Samid filed a patent for Antineoplastons AS2-1 .

They even had the audacity to include Burzynski as a reference.

"The invention described herein may be manufactured,

used and licensed by or for the government, for purposes..."

At the time, Burzynski had no idea this had happened,

but did have his suspicions when they began to openly test

Phenylacetate without him, and the National Cancer

Institute knew it.

In an April 1993 NCI memo,

distributed to those involved with Burzynski,

they state their concerns:

"Political issues are a real concern.

Congressman Bedell is concerned we are taking the Antineoplastons

away from Burzynski. Burzynski has patents on Antineoplastons."

"Since phenylacetic acid, or Phenylacetate,

may be the active component of Antineoplastons,

our involvement has become an issue."

Five months later, the United States of America and Dr. Dvorit Samid

file their second extended patent on Antineoplastons.

And, guess who else was in it?

In March of the following year,

America files it's most extensive updated Antineoplaston

patent to date, spanning one hundred and eleven pages.

Seven months later, they file a fourth one. June 6, 1995,

the United States government has a field day filing their fifth,

sixth, seventh, and eighth extended patent on Antineoplastons.

The following day, America files it's ninth, tenth,

and eleventh extended Antineoplaston patent.

And, a couple of months after the eleventh patent was filed,

Dr. Michael Friedman leaves hid position at the National Cancer

Institute, and becomes Deputy Commissioner of Operations

for the Food and Drug Administration,

working directly under Dr. David Kessler.

And by November of that year, after a decade of failed grand juries,

the United States of America's Food and Drug Administration

finally manages to indict Dr. Burzynski.

One month into America's criminal trial against Burzynski,

America's first patent on Antineoplaston AS2-1 is approved.

A month after America fails in their second trial against Burzynski,

their second and third Antineoplaston patents are approved.

Over the course of the next three years,

the United States patent office approves all

eleven copy-cat patents on Antineoplastons AS2-1 .

And as we know, all of this was being done based on the fact that

the United States, which is the National Institutes of Health,

together with a pharmaceutical company,

which is Elan Pharmaceuticals

was tying simply to steal my invention.

That's what they wanted.

It's not that we had successful visit from

the National Cancer Institute in which

they determined that "this treatment works great"

and they decided that we should go into Phase 2 clinical trials

which would be sponsored by them.

No.

This gave the idea of some high-ups at the FDA to

conspire with the pharmaceutical company

so that they could steal the invention from me and get it,

because it was good.

That's the whole story.

They knew that If I'd be still free, they won't be able to do it.

Because they knew that if I would sue them

they wouldn't have a chance in court

because we have had our patents before them.

So that's why they attempted to wipe me out financially,

to put me in prison,

to attack me from every possible angle:

FDA, which is the federal government, state government...

to be able to steal my invention.

That's the real thing from the National Cancer Institute

and Elan Pharmaceuticals.

They failed.

We survived, and we continue to move forward.

These patents are full of useful information.

Aside from noticing their blatant infringement,

"Compositions and Methods for Treating and Preventing Cancer",

using the distribution of Antineoplastons AS2-1's ingredients.

They enthusiastically state:

"The neoplastic conditions treatable by this method include:

neuroblastoma, leukemia, myelodisplasia, acute glioma,

prostate cancer, breast cancer, melanoma, lung cancer,

medulloblastoma, and lymphoma" to name a few.

They also point out how Antineoplastons

can also be used as a cancer preventative.

However, the most revealing piece of

information found in these patents is where they state:

"Current approaches to combat cancer rely primarily

on the use of chemicals and radiation

Rate this script:0.0 / 0 votes